Organization
Royal Melbourne Hospital
4 abstracts
Abstract
A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia.Org: City of Hope National Medical Center, Erasmus University Medical Center, Institut Paoli-Calmettes, Marseille, France, University Medical Center Groningen, MD Anderson Cancer Center,
Abstract
Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study.Org: The Peter MacCallum Cancer Centre, Royal Melbourne Hospital, The University of Melbourne, Department of Internal Medicine III, University Hospital Ulm, Klinik für Innere Medizin I, Hämatologie, Onkologie und Stammzelltransplantation Centrum für Chronische Immundefizienz (CCI),
Abstract
Phase III, international, multicentre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain.Org: National Cancer Center Japan, University of Notre Dame, Flinders University, Adelaide, SA, Australia, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Japanese Organisation for Research and Treatment of Cancer (JORTC) Data Center,
Abstract
A PILOT STUDY USING A GENERIC, INDIRECT UTILITY MEASURE, THE SF-6D IN RHEUMATOID ARTHRITISOrg: Rheumatology, Austin Health, Psychiatry Department, Basurto University Hospital, Bilbao, United Kingdom, Royal Melbourne Hospital, Melbourne, Australia,